Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Operating Expenses of $43.8 million for Q1 2026, up 15.81% year-over-year from $37.8 million in Q1 2025, and up 19.6% quarter-over-quarter from $36.6 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Operating Expenses history runs 6 years deep, the most recent figure standing at $43.8 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 15.81% year-over-year to $43.8 million; the TTM figure through Mar 2026 stood at $159.3 million (down 30.49% YoY), while the FY2025 annual figure was $153.3 million, down 61.88% from the prior year.
- Operating Expenses for Q1 2026 stood at $43.8 million, up from $36.6 million in the prior quarter.
- The five-year high for Operating Expenses was $210.8 million in Q1 2024, with the low at $36.0 million in Q3 2025.
- The 5-year median for Operating Expenses is $55.0 million (2022), against an average of $68.5 million.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 271.57% in 2022, then plunged 82.06% in 2025.
- Amylyx Pharmaceuticals' Operating Expenses stood at $66.5 million in 2022, then soared by 60.23% to $106.5 million in 2023, then sank by 62.46% to $40.0 million in 2024, then retreated by 8.46% to $36.6 million in 2025, then climbed by 19.6% to $43.8 million in 2026.
- Business Quant data shows AMLX's Operating Expenses at $43.8 million in Q1 2026, $36.6 million in Q4 2025, and $36.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 842.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 50.30 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 550.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | 45.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.69 Mn |
| Mar 31, 2026 | 43.78 Mn |
| Dec 31, 2025 | 36.61 Mn |
| Sep 30, 2025 | 36.03 Mn |
| Jun 30, 2025 | 42.86 Mn |
| Mar 31, 2025 | 37.80 Mn |
| Dec 31, 2024 | 39.99 Mn |
| Sep 30, 2024 | 76.08 Mn |
| Jun 30, 2024 | 75.26 Mn |
| Mar 31, 2024 | 210.77 Mn |
| Dec 31, 2023 | 106.52 Mn |
| Sep 30, 2023 | 83.97 Mn |
| Jun 30, 2023 | 78.02 Mn |
| Mar 31, 2023 | 73.48 Mn |
| Dec 31, 2022 | 66.48 Mn |
| Sep 30, 2022 | 55.03 Mn |
| Jun 30, 2022 | 54.25 Mn |
| Mar 31, 2022 | 47.81 Mn |
| Dec 31, 2021 | 28.32 Mn |
| Sep 30, 2021 | 23.20 Mn |